Nutshell Therapeutics Receives FDA Clearance for NRF2 Degrader Clinical Trial
Chinese biotech firm Nutshell Therapeutics has secured FDA clearance to begin U.S. clinical development for its NRF2-targeting drug candidate, NTS231, marking a significant step in cancer therapy research.
SHANGHAI – Nutshell Therapeutics has received clearance from the U.S. Food and Drug Administration (FDA) to initiate clinical development in the United States for its NRF2 degrader drug candidate, NTS231. This marks the first NRF2 degrader originating from China and the second globally to enter clinical development.
The development of NTS231 represents a notable advancement in efforts to therapeutically target the NRF2 pathway, which is a key driver of tumor survival and treatment resistance across multiple cancer types. Nutshell Therapeutics utilized its proprietary AI-driven drug discovery platform, ALLOSTAR™, to identify NTS231, a novel molecule that covalently binds to KEAP1 and induces the degradation of NRF2. The company achieved Investigational New Drug (IND) clearance within 24 months of target nomination, highlighting the AI-enabled acceleration of drug discovery.
Preclinical studies demonstrated that NTS231 exhibited significant efficacy in various solid tumor models, including lung cancer and head and neck cancers, associated with alterations in the NRF2 pathway. The drug candidate also showed potential for combination therapies with chemotherapy, targeted treatments, and antibody-drug conjugates (ADCs). Toxicology studies in rats and dogs indicated a favorable safety profile and a wide safety margin.
Constitutive activation of the NRF2 pathway, due to mutations in the NRF2, KEAP1, or CUL3 genes, is observed in approximately 12% of cancer patients globally. This patient population often responds poorly to existing targeted therapies and immunotherapies, underscoring the need for new treatment modalities. NTS231 offers a new therapeutic approach for these NRF2-driven cancers.